SILENCE THERAPEUTICS PLC Share Price Today: Live Updates & Key Insights

SILENCE THERAPEUTICS PLC share price today is $6.17, up -3.29%. The stock opened at $6.367 against the previous close of $6.38, with an intraday high of $6.4 and low of $6.1.

SILENCE THERAPEUTICS PLC Share Price Chart

SILENCE THERAPEUTICS PLC

us-stock
To Invest in {{usstockname}}
us-stock

SILENCE THERAPEUTICS PLC Share Price Performance

$6.17 -0.0329(-3.29%) SLN at 23 Mar 2026 03:14 PM Biotechnology
Lowest Today 6.1
Highest Today 6.4
Today’s Open 6.367
Prev. Close 6.38
52 Week High 7.91
52 Week Low 1.97
Day’s Range: Low 6.1 High 6.4
52-Week Range: Low 1.97 High 7.91
1 day return -
1 Week return -16.34
1 month return +21.34
3 month return -5.1
6 month return +20.98
1 year return +76.43
3 year return -30.62
5 year return -81.67
10 year return -

SILENCE THERAPEUTICS PLC Institutional Holdings

TCG Crossover Management, LLC 6.42

Siren, L.L.C. 6.16

Redmile Group, LLC 4.58

Lombard Odier Asset Management USA Corp 3.91

Nantahala Capital Management, LLC 3.27

Morgan Stanley - Brokerage Accounts 2.56

Vivo Capital, LLC 2.34

Nextech Invest, Ltd. 2.02

Ikarian Capital, LLC 1.91

Millennium Management LLC 1.40

MEDICAL BioHealth EUR Acc 1.20

5AM Venture Management, LLC 1.01

International Biotechnology Ord 0.94

apo Medical Opportunities R 0.66

SG Americas Securities, LLC 0.65

UBS Group AG 0.65

Citadel Advisors Llc 0.52

Ishara Investments LP 0.51

BOOTHBAY FUND MANAGEMENT, LLC 0.44

M28 Capital Management LP 0.39

HSBC Holdings PLC 0.37

Marshall Wace Asset Management Ltd 0.33

Bank of Montreal 0.33

iShares Biotechnology ETF 0.31

RIM Global Bioscience EUR 0.20

Galileo - Biotech Innovation Fund S USD 0.12

iShares Nasdaq US Biotech ETF USD Acc 0.07

WEALTHGATE Biotech Fund Inst 0.07

Vifag 2002 SICAV 0.06

Fidelity Nasdaq Composite Index 0.06

China Universal NASDAQ Bio-Tch ETF(QDII) 0.02

State Street® SPDR® S&P® Intl Sm Cp ETF 0.02

Steward Values Enhanced International I 0.01

Invesco Nasdaq Biotechnology ETF 0.01

ProShares Ultra Nasdaq Biotechnology 0.00

Blackstone Alternative Multi-Strategy I 0.00

GF NASDAQ Bio-Tech Idx QDII USD A 0.00

CREF Total Global Stock Account R3 0.00

SILENCE THERAPEUTICS PLC Market Status

Strong Buy: 3

Buy: 3

Hold: 0

Sell: 1

Strong Sell: 0

SILENCE THERAPEUTICS PLC Fundamentals

Market Cap 291.43 M

PB Ratio 4.8292

PE Ratio 0.0

Enterprise Value 198.45 M

Total Assets 131.44 M

Volume 255130

SILENCE THERAPEUTICS PLC Company Financials

Annual Revenue FY23:28041000 28.0M, FY22:17501000 17.5M, FY21:12415000 12.4M, FY20:5479000 5.5M, FY19:244000 0.2M

Annual Profit FY23:15210000 15.2M, FY22:6621000 6.6M, FY21:4959000 5.0M, FY20:1717000 1.7M, FY19:244000 0.2M

Annual Net worth FY23:-42618000 -42.6M, FY22:-40489000 -40.5M, FY21:-39410000 -39.4M, FY20:-32547000 -32.5M, FY19:-19582000 -19.6M

Quarterly Revenue Q3/2025:159000 0.2M, Q2/2025:224000 0.2M, Q1/2025:142000 0.1M, Q3/2024:1142000 1.1M, Q2/2024:598000 0.6M

Quarterly Profit Q3/2025:95000 0.1M, Q2/2025:139000 0.1M, Q1/2025:88000 0.1M, Q3/2024:-1632000 -1.6M, Q2/2024:-2040000 -2.0M

Quarterly Net worth Q3/2025:-20958000 -21.0M, Q2/2025:-27354000 -27.4M, Q1/2025:-28530000 -28.5M, Q3/2024:-27012000 -27.0M, Q2/2024:-15562000 -15.6M

About SILENCE THERAPEUTICS PLC & investment objective

Company Information Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.

Organisation Biotechnology

Employees 88

Industry Biotechnology

CEO Mr. Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.D

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

SILENCE THERAPEUTICS PLC FAQs

What is the share price of SILENCE THERAPEUTICS PLC today?

The current share price of SILENCE THERAPEUTICS PLC is $6.17.

Can I buy SILENCE THERAPEUTICS PLC shares in India?

Yes, Indian investors can buy SILENCE THERAPEUTICS PLC shares by opening an international trading and demat account with Motilal Oswal.

How to buy SILENCE THERAPEUTICS PLC shares in India?

You can easily invest in SILENCE THERAPEUTICS PLC shares from India by:

Can I buy fractional shares of SILENCE THERAPEUTICS PLC?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of SILENCE THERAPEUTICS PLC?

SILENCE THERAPEUTICS PLC has a market cap of $291.43 M.

In which sector does SILENCE THERAPEUTICS PLC belong?

SILENCE THERAPEUTICS PLC operates in the Biotechnology sector.

What documents are required to invest in SILENCE THERAPEUTICS PLC stocks?

To invest, you typically need:

What is the PE and PB ratio of SILENCE THERAPEUTICS PLC?

The PE ratio of SILENCE THERAPEUTICS PLC is N/A and the PB ratio is 4.83.